Processing

Please wait...

Settings

Settings

Goto Application

1. WO2005097194 - SUSTAINED RELEASE FORMULATION FOR ORAL ADMINISTRATION OF HMG-COA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF

Publication Number WO/2005/097194
Publication Date 20.10.2005
International Application No. PCT/KR2005/001021
International Filing Date 08.04.2005
IPC
A61K 47/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
47Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
A61P 9/10 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
9Drugs for disorders of the cardiovascular system
10for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
CPC
A61K 31/366
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
335having oxygen as the only ring hetero atom, e.g. fungichromin
365Lactones
366having six-membered rings, e.g. delta-lactones
A61K 9/145
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
145with organic compounds
A61K 9/146
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
146with organic macromolecular compounds
A61K 9/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
14Particulate form, e.g. powders, ; Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
16Agglomerates; Granulates; Microbeadlets ; ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
A61K 9/2077
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
9Medicinal preparations characterised by special physical form
20Pills, tablets, ; discs, rods
2072characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
2077Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
A61P 3/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
3Drugs for disorders of the metabolism
06Antihyperlipidemics
Applicants
  • HANMI PHARM. CO., LTD. [KR]/[KR] (AllExceptUS)
  • WOO, Jong-Soo [KR]/[KR] (UsOnly)
  • YI, Hong-Gi [KR]/[KR] (UsOnly)
  • CHI, Moon-Hyuk [KR]/[KR] (UsOnly)
  • RYU, Jae-Kuk [KR]/[KR] (UsOnly)
  • JUNG, Si-Young [KR]/[KR] (UsOnly)
  • KIM, Yong-Il [KR]/[KR] (UsOnly)
Inventors
  • WOO, Jong-Soo
  • YI, Hong-Gi
  • CHI, Moon-Hyuk
  • RYU, Jae-Kuk
  • JUNG, Si-Young
  • KIM, Yong-Il
Agents
  • JANG, Seongku
Priority Data
10-2004-002473410.04.2004KR
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) SUSTAINED RELEASE FORMULATION FOR ORAL ADMINISTRATION OF HMG-COA REDUCTASE INHIBITOR AND METHOD FOR THE PREPARATION THEREOF
(FR) PREPARATION A LIBERATION PROLONGEE DESTINEE A L'ADMINISTRATION ORALE D'UN INHIBITEUR DE LA HMG-COA REDUCTASE ET SON PROCEDE DE PREPARATION
Abstract
(EN)
The sustained release formulation for oral administration of an HMG-CoA reductase inhibitor of the present invention can be easily and economically prepared and is capable of maintaining a constant drug level in blood by slowly releasing the HMG-CoA reductase inhibitor at a uniform rate for 24 hrs. Accordingly, the sustained release formulation of the present invention can be effectively used for lowering blood cholesterol and triglyceride levels.
(FR)
La présente invention concerne une préparation à libération prolongée destinée à l'administration orale d'un inhibiteur de la HMG-CoA réductase et pouvant être préparée de manière facile et économique. Cette préparation permet de maintenir la concentration d'un médicament dans le sang à un niveau constant du fait de la lente libération de l'inhibiteur de HMG-CoA réductase à une vitesse uniforme pendant 24 heures. Par conséquent, la préparation à libération prolongée de la présente invention peut être utilisée efficacement pour abaisser le taux de cholestérol et de triglycérides dans le sang.
Latest bibliographic data on file with the International Bureau